Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can gene activity in gastric tumors predict chemotherapy response?

NCT ID NCT07787052

Knowledge-focused Sponsor: Centre Leon Berard Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 26, 2026 · Last updated Aug 27, 2026 · Updated 1 time

Summary

This study examines tissue samples from adults with gastric cancer who received chemotherapy before surgery. Researchers will analyze gene activity in the tumor and nearby lymph nodes to look for patterns linked to how well the cancer responded to treatment. The goal is to better understand the biology of gastric cancer and potentially identify markers that could inform future treatment strategies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could reveal why some gastric cancers respond better to chemotherapy, potentially guiding more personalized treatment decisions in the future.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly change patient care. The findings may not apply to all gastric cancer cases, and the sample size is small.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2024

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with non-metastatic resectable gastric and gastroesophageal junction adenocarcinoma, Stage IB to III treated with standard neoadjuvant chemotherapy, operated at Centre léon Bérard, with available tumor and lymph nodes samples

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients with histologically proven non-metastatic resectable gastric and gastroesophageal junction adenocarcinoma, Stage IB to III be treated with standard neoadjuvant chemotherapy * Knwon response to neoadjuvant chemotherapy as per TRG criteria * Surgery of primary tumor done at Centre Léon Bérard. Availability of archival FFPE tumor block from initial diagnosis with at least 20% of tumor cells and collected lymp nodes Exclusion Criteria: * Patient refusal to participate to this clinicobiological cohort

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastric adenocarcinoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastric cancer gastric neoplasm gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gastric cancers

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre Léon Bérard

    RECRUITING

    Lyon, 69008, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.